GANX Earnings & Financial Statements
Gain Therapeutics, Inc.
$1.33
+$0.01(+0.76%)
24
Overall
40
Value
10
Tech
23
Quality
Market Cap
$57.61M
Volume
501.27K
52W Range
$1.53 - $4.34
Target Price
$7.20
GANX earnings and financial statements: Gain Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
GANX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | $55.2K | $140.1K | $165.0K |
| Operating income | -$18.71M | -$20.35M | -$22.25M | -$17.78M | -$13.83M |
| EBITDA | -$19.45M | -$20.15M | -$22.10M | -$17.71M | -$13.88M |
| Net income | -$20.16M | -$20.41M | -$22.27M | -$17.59M | -$13.89M |
| EPS (diluted) | $-0.61 | $-0.89 | $-1.71 | $-1.48 | $-1.37 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $22.82M | $12.12M | $18.61M | $24.10M | $38.99M |
| Total liabilities | $4.25M | $4.78M | $6.03M | $5.22M | $4.17M |
| Shareholders’ equity | $18.56M | $7.34M | $12.58M | $18.88M | $34.82M |
| Cash and equivalents | $20.84M | $10.39M | $11.79M | $7.31M | $36.88M |
| Long-term debt | $511.3K | $381.9K | $678.9K | $937.0K | $1.29M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$18.47M | -$18.87M | -$18.87M | -$14.69M | -$12.37M |
| Capital expenditure | - | -$22.5K | -$15.4K | -$119.0K | -$94.2K |
| Free cash flow | -$18.47M | -$18.90M | -$18.88M | -$14.81M | -$12.46M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GANX | $1.33 | +0.8% | 501.27K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |